Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824194 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
A Phase 3 study of Pneumococcal Immunization, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,320
- Enrollment target
- 20
- Study locations
NCT06824194: Recruiting Phase 3 study of Pneumococcal Immunization, sponsored by Sanofi.
NCT06824194 is a Phase 3 study of Pneumococcal Immunization that is actively recruiting participants, run by Sanofi. The registered enrollment target is 2,320 participants, above the 823-participant average among 3 other Pneumococcal Immunization trials with a reported enrollment target (182% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06824194, a Phase 3 study of Pneumococcal Immunization, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.
Primary Outcome
Number of participants experiencing solicited and unsolicited immediate AEs
Conditions Studied
Interventions
- BIOLOGICAL PCV21 vaccine
- BIOLOGICAL Prevnar 20 vaccine
- BIOLOGICAL M-M-R II vaccine
- BIOLOGICAL Rotarix
- BIOLOGICAL RotaTeq
Study Locations (20)
California
- Helping Hands Healthcare Group - Fullerton- Site Number : 8400063 - Fullerton
- Advanced Investigative Medicine- Site Number : 8400055 - Hawthorne
- Century Research Institute- Site Number : 8400118 - Huntington Park
- Matrix Clinical Research - Huntington Park- Site Number : 8400117 - Huntington Park
- Matrix Clinical Research - Los Angeles- Site Number : 8400026 - Los Angeles
- Matrix Clinical Research - Los Angeles- Site Number : 8400123 - Los Angeles
- Alliance Research Institute - Lynwood- Site Number : 8400099 - Lynwood
- Madera Family Medical Group- Site Number : 8400011 - Madera
- FOMAT-Golden Valley Health Centers- Site Number : 8400084 - Merced
- Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400072 - Palo Alto
- Center for Clinical Trials - Paramount- Site Number : 8400100 - Paramount
- Integrated Clinical Research LLC- Site Number : 8400027 - Sherman Oaks
- Emanate Health - Queen of the Valley Hospital- Site Number : 8400105 - West Covina
Alabama
- Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400013 - Birmingham
- University of Alabama at Birmingham- Site Number : 8400130 - Birmingham
- Lakeview Clinical Research- Site Number : 8400054 - Guntersville
- Midway Medical Clinic- Site Number : 8400091 - Oneonta
Arkansas
- The Children's Clinic- Site Number : 8400079 - Jonesboro
- Helios CR, Inc. - Little Rock- Site Number : 8400090 - Sherwood
Arizona
- Noble Clinical Research- Site Number : 8400121 - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,320 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2027-05-12 |
| Phase | Phase 3 |
What NCT06824194 shows while recruiting
NCT06824194 is an interventional study that assigns participants to a tested intervention. Its 2,320 participants enrollment target places it among the larger protocols in the corpus, above the 823-participant average among 3 other Pneumococcal Immunization trials with a reported enrollment target (182% higher).
The record links to 1 condition, with Pneumococcal Immunization appearing as the primary indexed condition, and to 5 interventions - of which PCV21 vaccine is the first listed.
NCT06824194 names 20 study sites across 4 states, led by California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06824194 about?
NCT06824194 is a clinical study titled "Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age". This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The stu...
What is the current status of trial NCT06824194?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,320 participants. The study started on 2025-02-18. Estimated completion is 2027-05-12.
What conditions does trial NCT06824194 study?
This clinical trial studies the following conditions: Pneumococcal Immunization.
What interventions are being tested in trial NCT06824194?
The interventions under investigation include: PCV21 vaccine (BIOLOGICAL), Prevnar 20 vaccine (BIOLOGICAL), M-M-R II vaccine (BIOLOGICAL), Rotarix (BIOLOGICAL), RotaTeq (BIOLOGICAL).
Who is sponsoring clinical trial NCT06824194?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824194 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Immunization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
ACTIVE NOT RECRUITING · Phase 3
-
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05700760 · 2,320 participants · NA
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
- NCT06679140 · 2,330 participants · Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- NCT05485961 · 2,310 participants · Phase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI